BioSpace News Archive

Beactica Therapeutics AB announced that its TEAD programme has been selected for a late-breaking presentation at the American Association for Cancer Research’s Annual Meeting 2024.

Numab Therapeutics AG and Ono Pharmaceutical Co., Ltd. announced a global research, development and commercialization collaboration for NM49, a multi-specific antibody designed to activate tumor associated macrophage phagocytosis for the treatment of cancers and identified through Numab’s proprietary discovery and engineering technology platform.

TILT Biotherapeutics announces it has been selected by the U.S. Department of Defense, America’s largest government agency, to receive a USD 2M grant for a three-year project on treatment for ovarian cancer using the company’s TILT-123 asset.

Latigo Biotherapeutics Inc., a clinical-stage biotechnology company developing best-in-class non-opioid pain medicines that target pain at its source, announced its emergence from stealth with a $135 million Series A financing.

Encision Inc., a medical device company owning patented Active Electrode Monitoring Technology that prevents dangerous radiant energy burns in minimally invasive surgery, announced financial results for its fiscal 2024 third quarter that ended December 31, 2023.

Zymeworks Inc., a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, announced that management will report its fourth quarter 2023 financial results after market close on March 6, 2024.

Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, reported financial results for the fourth quarter and year ended December 31, 2023.

Biotricity Inc. provided selected preliminary financial results for its fiscal third quarter 2024 results, ended December 31, 2023, that include record gross margins and record operational efficiency.

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces continued encouraging clinical findings from the most recent follow-up visit of the first patient enrolled in Deltacel-01, the Company’s Phase 1 clinical trial evaluating Deltacel ™ for the treatment of stage 4 metastatic non-small lung cancer.

Ashvattha Therapeutics today announced that members of its senior management team will participate in two upcoming investor conferences.